The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
Julie R. Brahmer
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Leora Horn
Consultant or Advisory Role - Astellas Pharma (U); Boehringer Ingelheim (U); Genentech (U); OSI Pharmaceuticals (U)
Research Funding - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Genentech; Xcovery
Scott J. Antonia
No relevant relationships to disclose
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Leena Gandhi
No relevant relationships to disclose
Lecia V. Sequist
Employment or Leadership Position - Bristol-Myers Squibb
Vindira Sankar
Employment or Leadership Position - Bristol-Myers Squibb
Christoph Matthias Ahlers
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Scott N. Gettinger
No relevant relationships to disclose